ONCY
ONCY clinical trials: ONCOLYTICS BIOTECH INC
Every trial on ClinicalTrials.gov where ONCOLYTICS BIOTECH INC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 23
- Trials linked
- 15
- As lead sponsor
- 8
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ONCY on the catalyst calendar · ONCY registry changes
- Primary completion Aug 30, 2027Sponsor estimatePhase 2NCT07446322FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal...Oncolytics Biotech · Ras-mutated Metastatic Colorectal CancerRecruitingONCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 30, 2027Sponsor estimatePhase 1/Phase 2NCT07280377A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and AtezolizumabOncolytics Biotech · Anal Cancer MetastaticActive, not recruitingONCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 1, 2022ActualPhase 2NCT04215146A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus...Oncolytics Biotech · Breast Cancer MetastaticActive, not recruitingONCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 20, 2022ActualEarly Phase 1NCT04102618A Window-of-opportunity Study of Pelareorep in Early Breast CancerOncolytics Biotech · Breast CancerTerminatedONCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2018ActualPhase 1NCT01274624Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal CancerOncolytics Biotech · KRAS Mutant Metastatic Colorectal CancerCompletedONCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2018ActualPhase 1NCT02620423Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic AdenocarcinomaOncolytics Biotech · Pancreatic AdenocarcinomaCompletedONCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2017Sponsor estimatePhase 1NCT02723838Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional...Oncolytics Biotech · Muscle-invasive Transitional Cell Carcinoma of the BladderWithdrawnONCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2013ActualPhase 2NCT00998192A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the LungOncolytics Biotech · Metastatic or Recurrent Squamous Cell Carcinoma of the LungCompletedONCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2015ActualPhase 2NCT00861627Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR ActivationOncolytics Biotech · Carcinoma, Non-small Cell LungCompletedONCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2013ActualPhase 2NCT00998322A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic AdenocarcinomaOncolytics Biotech · Metastatic Pancreatic AdenocarcinomaCompletedONCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2014ActualPhase 2NCT00984464Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic MelanomaOncolytics Biotech · Metastatic MelanomaCompletedONCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2012ActualPhase 3NCT01166542Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck CancersOncolytics Biotech · Carcinoma, Squamous Cell of the Head and NeckCompletedONCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2011ActualPhase 2NCT00753038Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck CarcinomaOncolytics Biotech · Carcinoma, Squamous Cell of the Head and NeckCompletedONCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2010ActualPhase 1NCT00528684Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant GliomasOncolytics Biotech · Malignant GliomaCompletedONCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2011ActualPhase 2NCT00503295Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the LungOncolytics Biotech · OsteosarcomaCompletedONCYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2025Sponsor estimatePhase 2NCT04445844INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE StudyMridula George, MD · Anatomic Stage IV Breast Cancer AJCC v8Active, not recruitingONCYCollaboratorINCYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 10, 2022ActualPhase 1NCT03605719Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple MyelomaEmory University · Recurrent Plasma Cell MyelomaCompletedONCYCollaboratorBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 19, 2022ActualPhase 1NCT02514382Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaUniversity of Southern California · Recurrent Plasma Cell MyelomaCompletedONCYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 26, 2016ActualPhase 2NCT01708993Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage TherapyCanadian Cancer Trials Group · Non Small Cell Lung CancerCompletedONCYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 18, 2016ActualPhase 2NCT01656538A Study of Reolysin For Patients With Advanced/Metastatic Breast CancerCanadian Cancer Trials Group · Metastatic Breast CancerCompletedONCYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 18, 2017ActualPhase 2NCT01622543Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal CancerCanadian Cancer Trials Group · Colorectal CancerCompletedONCYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 26, 2016ActualPhase 2NCT01619813Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate CancerCanadian Cancer Trials Group · Prostate CancerCompletedONCYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 1, 2021Sponsor estimatePhase 1NCT03015922Viral Immunotherapy in Relapsed/Refractory Multiple MyelomaUniversity of Leeds · Multiple MyelomaUnknown statusONCYCollaboratorBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 23 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner